Gene therapy for severe combined immunodeficiency

Annual Review of Medicine

Volumn 56, Issue , 2005, Pages 585-602

  Cavazzana Calvo, Marina ^a   Lagresle, Chantal ^a   Hacein Bey Abina, Salima ^a   Fischer, Alain ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Allogeneic bone marrow transplantation; Hematopoietic stem cell; Retrovirus

Indexed keywords

ADENOSINE DEAMINASE; CD34 ANTIGEN; GANCICLOVIR; GENE PRODUCT; INTERLEUKIN 2 RECEPTOR ALPHA; JANUS KINASE 3; PEGYLATED ADENOSINE DEAMINASE; PROTEIN KINASE ZAP 70; PROTEIN LMO 2; RAG2 PROTEIN; RETROVIRUS VECTOR; T LYMPHOCYTE RECEPTOR GAMMA CHAIN; THYMIDINE KINASE; UNCLASSIFIED DRUG;

ADENOSINE DEAMINASE DEFICIENCY; ALLOGENIC BONE MARROW TRANSPLANTATION; B LYMPHOCYTE; CAUSE OF DEATH; CLINICAL FEATURE; CLINICAL TRIAL; COMBINED IMMUNODEFICIENCY; DISEASE CLASSIFICATION; DISEASE SEVERITY; GENE MUTATION; GENE THERAPY; GENE TRANSFER; GENOTYPE; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNE SYSTEM; IMMUNITY; LONG TERMINAL REPEAT; LYMPHOCYTE DIFFERENTIATION; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; RARE DISEASE; REVIEW; SIDE EFFECT; SUICIDE GENE; T LYMPHOCYTE; T LYMPHOCYTE RECEPTOR GENE; VIRAL GENE DELIVERY SYSTEM;

B-LYMPHOCYTES; DNA MUTATIONAL ANALYSIS; GENE THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; LYMPHOCYTE ACTIVATION; PHENOTYPE; SEVERE COMBINED IMMUNODEFICIENCY; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS;

EID: 14544269487     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.56.090203.104142     Document Type: Review

References (69)

1. Buckley RH. 2002. Primary immunodeficiency diseases: dissectors of the immune system. Immunol. Rev. 185:206-19
2. Fischer A. 2004. Human primary immunodeficiency diseases: a perspective. Nat. Immunol. 5:23-30
3. Notarangelo LD, Giliani S, Mazza C, et al. 2000. Of genes and phenotypes: the immunological and molecular spectrum of combined immune deficiency. Defects of the gamma(c)-JAK3 signaling pathway as a model. Immunol. Rev. 178:39-48
4. Candotti F, Notarangelo L, Visconti R, et al. 2002. Molecular aspects of primary immunodeficiencies: lessons from cytokine and other signaling pathways. J. Clin. Invest. 109:1261-69
5. deVillartay JP, Poinsignon C, de Chasseval R, et al. 2003. Human and animal models of V(D)J recombination deficiency. Curr. Opin. Immunol. 15:592-98
6. Dadi H, Simon AJ, Roifman CM. 2003. Effect of CD3δ deficiency on maturation of α/β and γ/δ T-cell lineages in severe combined immunodeficiency. N. Engl. J. Med. 6:349
7. Kung C, Pingel JT, Heikinheimo MK, et al. 2000. Mutations in the tyrosine phosphatase CD45 gene in a child with severe combined immunodeficiency disease. Nat. Med. 6:343-45
8. De Saint Basile G , Geissmann F, Flori E, et al. 2004. Severe combined immunodeficiency caused by deficiencies in either the δ or ε CD3 subunit. J. Clin. Invest. In press
9. Small TN, Wall DA, Kurtzberg J, et al. 1999. Association of reticular dysgenesis (thymic alymphoplasia and congenital aleukocytosis) with bilateral sensorineural deafness. J. Pediatr. 135:387-89
10. + T cells due to ZAP-70 deficiency. Cell Immunol. 165:110-17
11. Villard J, Masternak K, Lisowska-Grospierre B, et al. 2001. MHC class II deficiency: a disease of gene regulation. Medicine (Baltimore) 80:405-18
12. Dror Y, Grunebaum E, Hitzler J, et al. 2004. Purine nucleoside phosphorylase deficiency associated with a dysplastic marrow morphology. Pediatr. Res. 55:72-77
13. Villa A, Sobacchi C, Notarangelo LD, et al. 2001. V(D)J recombination defects in lymphocytes due to RAG mutations: severe immunodeficiency with a spectrum of clinical presentations. Blood 97:1-8
14. Gatti RA, Meuwissen HJ, Allen HD, et al. 1968. Immunological reconstitution of sex-linked lymphopenic immunological deficiency. Lancet 2:1366-69
15. Bach FH, Albertini RJ, Joo P, et al. 1968. Bone-marrow transplantation in a patient with the Wiskott-Aldrich syndrome. Lancet 2:1364-66
16. Antoine C, Muller S, Cant A, et al. 2003. Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968-99. Lancet 361:553-60
17. Bertrand Y, Landais P, Friedrich W, et al. 1999. Influence of severe combined immunodeficiency phenotype on the outcome of HLA non-identical, T-cell-depleted bone marrow transplantation: a retrospective European survey from the European Group for Bone Marrow Transplantation and the European Society for Immunodeficiency. J. Pediatr. 134:40-48
18. Buckley RH, Schiff SE, Schiff RI, et al. 1999. Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N. Engl. J. Med. 340:508-16
19. Sarzotti M, Patel DD, Li X, et al. 2003. T cell repertoire development in humans with SCID after nonablative allogeneic marrow transplantation. J. Immunol. 170: 2711-18
20. Buckley RH. 2004. Molecular defects in human severe combined immunodeficiency and approaches to immune reconstitution. Annu. Rev. Immunol. 22:25-55
21. Myers LA, Patel DD, Puck JM, et al. 2002. Hematopoietic stem cell transplantation for severe combined immunodeficiency in the neonatal period leads to superior thymic output and improved survival. Blood 99:872-78
22. Hirschhorn R, Yang DR, Puck JM, et al. 1996. Spontaneous in vivo reversion to normal of an inherited mutation in a patient with adenosine deaminase deficiency. Nat. Genet. 13:290-95
23. Bousso P, Wahn V, Douagi I, et al. 2000. Diversity, functionality, and stability of the T cell repertoire derived in vivo from a single human T cell precursor. Proc. Natl. Acad. Sci. USA 97:274-78
24. Wada T, Schurman SH, Otsu M, et al. 2001. Somatic mosaicism in Wiskott-Aldrich syndrome suggests in vivo reversion by a DNA slippage mechanism. Proc. Natl. Acad. Sci. USA 98:8697-702
25. Konno A, Wada T, Schurman SH, et al. 2004. Differential contribution of Wiskott-Aldrich syndrome protein to selective advantage in T- and B-cell lineages. Blood 103:676-78
26. Hirschhorn R. 2003. In vivo reversion to normal of inherited mutations in humans. J. Med. Genet. 40:721-28
27. Stephan V, Wahn V, Le Deist F, et al. 1996. Atypical X-linked severe combined immunodeficiency due to possible spontaneous reversion of the genetic defect in T cells. N. Engl. J. Med. 335:1563-67
28. - X-linked severe combined immunodeficiency hematopoietic progenitor cells in murine fetal thymic organ cultures. Blood 96:4090-97
29. Candotti F, Johnston JA, Puck JM, et al. 1996. Retroviral-mediated gene correction for X-linked severe combined immunodeficiency. Blood 87:3097-102
30. Taylor N, Uribe L, Smith S, et al. 1996. Correction of interleukin-2 receptor function in X-SCID lymphoblastoid cells by retrovirally mediated transfer of the gamma-c gene. Blood 87:3103-7
31. Otsu M, Sugamura K, Candotti F. 2001. Lack of dominant-negative effects of a truncated γc on retroviral-mediated gene correction of immunodeficient mice. Blood 97:1618-24
32. Hacein-Bey S, Gross F, Nusbaum P, et al. 2001. Optimization of retroviral gene transfer protocol to maintain the lymphoid potential of progenitor cells. Hum. Gene Ther. 12:291-301
33. Hanenberg H, Xiao XL, Dilloo D, et al. 1996. Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells. Nat. Med. 2:876-82
34. Soudais C, Tusjino S, Sharara LI, et al. 2000. Stable and functional lymphoid reconstitution of common cytokine receptor gamma chain deficient mice by retroviral-mediated gene transfer. Blood 95:3071-77
35. Lo M, Bloom ML, Imada K, et al. 1999. Restoration of lymphoid populations in a murine model of X-linked severe combined immunodeficiency by a gene-therapy approach. Blood 94:3027-36
36. Otsu M, Anderson SM, Bodine DM, et al. 2000. Lymphoid development and function in X-linked severe combined immunodeficiency mice after stem cell gene therapy. Mol. Ther. 1:145-53
37. Bunting KD, Sangster MY, Ihle JN, et al. 1998. Restoration of lymphocyte function in Janus kinase 3-deficient mice by retroviral-mediated gene transfer. Nat. Med. 4:58-64
38. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, et al. 2000. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288:669-72
39. Hacein-Bey-Abina S, Le Deist F, Carlier F, et al. 2002. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N. Engl. J. Med. 346:1185-93
40. Deleted in proof
41. Gaspar B, Parsley KL, Howe S, et al. 2004. Successful gene therapy of SCID-X1 using a pseudotyped gamma retroviral vector. Lancet. In press
42. Zennou V, Petit C, Guetard D, et al. 2000. HIV-1 genome nuclear import is mediated by a central DNA flap. Cell 101:173-85
43. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. 2003. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302:415-19
44. Royer-Pokora B, Loos U, Ludwig WD. 1991. TTG-2, a new gene encoding a cysteine-rich protein with the LIM motif, is overexpressed in acute T-cell leukaemia with the t(11;14)(p13;q11). Oncogene 6: 1887-93
45. Neale GA, Rehg JE, Goorha RM. 1995. Ectopic expression of rhombotin-2 causes selective expansion of CD4- CD8- lymphocytes in the thymus and T-cell tumors in transgenic mice. Blood 86: 3060-71
46. Yamada Y, Warren AJ, Dobson C, et al. 1998. The T cell leukemia LIM protein Lmo2 is necessary for adult mouse hematopoiesis. Proc. Natl. Acad. Sci. USA 95:3890-95
47. McCormack MP, Rabbitts TH. 2004. Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 350:913-22
48. Li Z, Dullmann J, Schiedlmeier B, et al. 2002. Murine leukemia induced by retroviral gene marking. Science 296:497
49. Baum C, Dullmann J, Li Z, et al. 2003. Side effects of retroviral gene transfer into hematopoietic stem cells. Blood 101:2099-114
50. Dave UP, Jenkins NA, Copeland NG. 2004. Gene therapy insertional mutagenesis insights. Science 303:333
51. Fischer A, Hacein-Bey Abina S, et al. 2004. LM02 and gene therapy for severe combined immunodeficiency. N. Engl. J. Med. 350:2526-27
52. Recillas-Targa F, Pikaart MJ, Burgess-Beusse B, et al. 2002. Position-effect protection and enhancer blocking by the chicken beta-globin insulator are separable activities. Proc. Natl. Acad. Sci. USA 99:6883-88
53. Hoogerbrugge PM, van Beusechem VW, Fischer A, et al. 1996. Bone marrow gene transfer in three patients with adenosine deaminase deficiency. Gene. Ther. 3:179-83
54. Bordignon C, Notarangelo LD, Nobili N, et al. 1995. Gene therapy in peripheral blood lymphocytes and bone marrow for ADA-immunodeficient patients. Science 270:470-75
55. Aiuti A, Slavin S, Aker M, et al. 2002. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 296:2410-13
56. + cells in ADA-deficient SCID neonates. Nat. Med. 4:775-80
57. Muul LM, Tuschong LM, Soenen SL, et al. 2003. Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial. Blood 101:2563-69
58. Aiuti A, Vai S, Mortellaro A, et al. 2002. Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement. Nat. Med. 8: 423-25
59. Robbins PB, Skelton DC, Yu XJ, et al. 1998. Consistent, persistent expression from modified retroviral vectors in murine hematopoietic stem cells. Proc. Natl. Acad. Sci. USA 95:10182-87
60. -/- mice: sustained correction of the immunodeficiency. Blood 22:22
61. Taylor N, Bacon KB, Smith S, et al. 1996. Reconstitution of T cell receptor signaling in ZAP-70-deficient cells by retroviral transduction of the ZAP-70 gene. J. Exp. Med. 184:2031-36
62. Klein C, Nguyen D, Liu CH, et al. 2003. Gene therapy for Wiskott-Aldrich syndrome: rescue of T-cell signaling and amelioration of colitis upon transplantation of retrovirally transduced hematopoietic stem cells in mice. Blood 101:2159-66
63. Pawliuk R, Westerman KA, Fabry ME, et al. 2001. Correction of sickle cell disease in transgenic mouse models by gene therapy. Science 294:2368-71
64. Kuramoto K, Follman D, Hematti P, et al. 2004. The impact of low-dose busulfan on clonal dynamics in non-human primates. Blood 4:4
65. Olivares EC, Hollis RP, Chalberg TW, et al. 2002. Site-specific genomic integration produces therapeutic Factor IX levels in mice. Nat. Biotechnol. 20:124-28
66. Gruenert DC, Bruscia E, Novelli G, et al. 2003. Sequence-specific modification of genomic DNA by small DNA fragments. J. Clin. Invest. 112:637-41
67. Krosl J, Austin P, Beslu N, et al. 2003. In vitro expansion of hematopoietic stem cells by recombinant TAT-HOXB4 protein. Nat. Med. 9:1428-32
68. Amsellem S, Pflumio F, Bardinet D, et al. 2003. Ex vivo expansion of human hematopoietic stem cells by direct delivery of the HOXB4 homeoprotein. Nat. Med. 9:1423-27
69. Reya T, Duncan AW, Ailles L, et al. 2003. A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature 423:409-14